Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Gabrieli, Arianna"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-10 z 29
Tytuł:
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
Autorzy:
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA.
Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Dang HV; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA.
McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Bowen J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Minola A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
De Marco A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Guarino B; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bianchi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Lauron EJ; Vir Biotechnology, San Francisco, CA 94158, USA.
Tucker H; Vir Biotechnology, San Francisco, CA 94158, USA.
Zhou J; Vir Biotechnology, San Francisco, CA 94158, USA.
Peter A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA.
Wojcechowskyj JA; Vir Biotechnology, San Francisco, CA 94158, USA.
Case JB; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Chen RE; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA 94158, USA.
Meury M; Vir Biotechnology, San Francisco, CA 94158, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA.
Spreafico R; Vir Biotechnology, San Francisco, CA 94158, USA.
Dillen J; Vir Biotechnology, San Francisco, CA 94158, USA.
Ng C; Vir Biotechnology, San Francisco, CA 94158, USA.
Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Culap K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Schmid MA; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Cameroni E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Riva A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.
Gabrieli A; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.
Galli M; III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.
Pizzuto MS; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.
Diamond MS; Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; Washington University School of Medicine, St. Louis, MO, USA.; UTSouthwestern Medical Center, Dallas, TX, USA.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Corti D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Fink K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. .
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2020 Nov 20; Vol. 370 (6519), pp. 950-957. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
Betacoronavirus/*immunology
Coronavirus Infections/*prevention & control
Pandemics/*prevention & control
Peptidyl-Dipeptidase A/*immunology
Pneumonia, Viral/*prevention & control
Spike Glycoprotein, Coronavirus/*antagonists & inhibitors
Amino Acid Motifs/immunology ; Angiotensin-Converting Enzyme 2 ; Animals ; Antibodies, Neutralizing/administration & dosage ; Antibodies, Neutralizing/isolation & purification ; Antibodies, Viral/administration & dosage ; Antibodies, Viral/isolation & purification ; CHO Cells ; COVID-19 ; Coronavirus Infections/therapy ; Cricetinae ; Cricetulus ; Cryoelectron Microscopy ; HEK293 Cells ; Humans ; Immunodominant Epitopes/chemistry ; Immunodominant Epitopes/immunology ; Microscopy, Electron ; Pneumonia, Viral/therapy ; Protein Domains/immunology ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immunogenicity of two doses of BNT162b2 and mRNA‐1273 vaccines for solid cancer patients on treatment with or without a previous SARS‐CoV‐2 infection.
Autorzy:
La Verde, Nicla
Riva, Agostino
Cona, Maria Silvia
Gabrieli, Arianna
Cattaneo, Monica
Fasola, Cinzia
Lipari, Giuseppe
De Stradis, Claudia
Favorito, Valentina
Lombardi Stocchetti, Benedetta
Chizzoniti, Davide
Covizzi, Alice
Rulli, Eliana
Galli, Francesca
Ruggieri, Lorenzo
Gambaro, Anna
Ferrario, Sabrina
Dalu, Davide
Tarkowski, Maciej S.
Pokaż więcej
Temat:
CANCER vaccines
IMMUNE response
CANCER patients
VACCINE immunogenicity
COVID-19 vaccines
Źródło:
International Journal of Cancer; Feb2023, Vol. 152 Issue 4, p661-671, 11p
Przedsiębiorstwo/ jednostka:
BIONTECH SE
PFIZER Inc.
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-10 z 29

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies